| 存储条件 |
|---|
| Product Name | EGFR |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | Avian erythroblastic leukemia viral (v erb b) oncogene homolog antibody Cell growth inhibiting protein 40 antibody Cell proliferation inducing protein 61 antibody EGF R antibody EGFR antibody EGFR_HUMAN antibody Epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog) antibody Epidermal growth factor receptor (erythroblastic leukemia viral (v erb b) oncogene homolog avian) antibody Epidermal growth factor receptor antibody erb-b2 receptor tyrosine kinase 1 antibody ERBB antibody ERBB1 antibody Errp antibody HER1 antibody mENA antibody NISBD2 antibody Oncogen ERBB antibody PIG61 antibody Proto-oncogene c-ErbB-1 antibody Receptor tyrosine protein kinase ErbB 1 antibody Receptor tyrosine-protein kinase ErbB-1 antibody SA7 antibody Species antigen 7 antibody Urogastrone antibody v-erb-b Avian erythroblastic leukemia viral oncogen homolog antibody wa2 antibody Wa5 antibody |
| Product description | The EGF receptor family comprises several related receptor tyrosine kinases that are frequently overexpressed in a variety of carcinomas. Members of this receptor family include EGFR (HER1), Neu (ErbB-2, HER2), ErbB-3 (HER3) and ErbB-4 (HER4), which form either homodimers or heterodimers upon ligand binding. Exons in the EGFR gene product are frequently either deleted or duplicated to produce deletion mutants (DM) or tandem duplication mutants (TDM), respectively, which are detected at various molecular weights. EGFR binds several ligands, including epidermal growth factor (EGF), transforming growth factor α (TGFα), Amphiregulin and heparin binding-EGF (HB-EGF). Ligand binding promotes the internalization of EGFR via Clathrin-coated pits and its subsequent degradation in response to its intrinsic tyrosine kinase. EGFR is involved in organ morphogenesis and maintenance and repair of tissues, but upregulation of EGFR is associated with tumor progression. The oncogenic effects of EGFR include initiation of DNA synthesis, enhanced cell growth, invasion and metastasis. Abrogation of EGFR results in cell cycle arrest, apoptosis or dedifferentiation of cancer cells, suggesting that EGFR may be an effective therapeutic target. |
| Immunogen | Peptide |
| Clonality | Polyclonal |
|---|---|
| Isotype | IgG |
| Host Species | Rabbit |
| Tested Applications | WBICCIHC |
| WB:1:500-1:1000 ICC:1:50-1:200 IHC:1:50-1:200 | |
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Alternative Names | Avian erythroblastic leukemia viral (v erb b) oncogene homolog antibody Cell growth inhibiting protein 40 antibody Cell proliferation inducing protein 61 antibody EGF R antibody EGFR antibody EGFR_HUMAN antibody Epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog) antibody Epidermal growth factor receptor (erythroblastic leukemia viral (v erb b) oncogene homolog avian) antibody Epidermal growth factor receptor antibody erb-b2 receptor tyrosine kinase 1 antibody ERBB antibody ERBB1 antibody Errp antibody HER1 antibody mENA antibody NISBD2 antibody Oncogen ERBB antibody PIG61 antibody Proto-oncogene c-ErbB-1 antibody Receptor tyrosine protein kinase ErbB 1 antibody Receptor tyrosine-protein kinase ErbB-1 antibody SA7 antibody Species antigen 7 antibody Urogastrone antibody v-erb-b Avian erythroblastic leukemia viral oncogen homolog antibody wa2 antibody Wa5 antibody |
|---|---|
| Molecular Weight(MW) | 175 kDa |
| Cellular Localization | Secreted and Cell membrane. Endoplasmic reticulum membrane. |
| SwissProt ID | P00533 |
|---|
Application
Fig1: Western blot analysis of EGFR on different cell lysate using anti-EGFR antibody at 1/1,000 dilution. Positive control：Lane1: HelaLane2: HUVECLane3: A431
Application
Fig2: ICC staining EGFR in A431 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Application
Fig3: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-EGFR antibody. Counter stained with hematoxylin.
Application
Fig4: Immunohistochemical analysis of paraffin-embedded human lung cancer tissue using anti-EGFR antibody. Counter stained with hematoxylin.
Application
Fig5: Immunohistochemical analysis of paraffin-embedded human liver tissue using anti-EGFR antibody. Counter stained with hematoxylin.
Application
Fig6: Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-EGFR antibody. Counter stained with hematoxylin.
Application
Fig7: Immunohistochemical analysis of paraffin-embedded 2 kidney tissue using anti-EGFR antibody. Counter stained with hematoxylin.| Positive Control | Hela, HUVEC, A431, human tonsil tissue, human lung cancer tissue, human liver tissue, human kidney tissue, 2 liver tissue, 2 kidney tissue. |
|---|---|
| Application Notes | WB:1:500-1:1000 ICC:1:50-1:200 IHC:1:50-1:200 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
抱歉，暂无相关文献
